Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M

Natera has acquired Foresight Diagnostics in a high‑value deal, advancing the company’s leadership in precision oncology. Foresight’s ultrasensitive MRD technology—built on foundational science developed at Stanford University—has been further supported and strengthened through its partnership with CU Anschutz Innovations. This milestone reflects the growing impact of CU Anschutz‑supported innovators as they help translate breakthrough science into tools that improve cancer detection and patient care.